{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:56:25Z","timestamp":1790920585216,"version":"4.1.0"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,11,23]],"date-time":"2011-11-23T00:00:00Z","timestamp":1322006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The purpose of the study was to compare, using data from Observation of Illicit Psychotropic Substances or Non\u2010medical Used Medications (OPPIDUM) surveys, first, the profile of buprenorphine users and their modalities of buprenorphine use from 2006 to 2008 and, second, two subgroups: brand\u2010name and generic buprenorphine users in 2008.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>OPPIDUM is an annual, nationwide, multicentric, cross\u2010sectional survey, including buprenorphine users followed in specialised centres dedicated to drug dependence. The evolution of the profile during three consecutive years (2006, 2007 and 2008) was analysed using Cochran\u2010Armitage test for trend. A multivariate regression analysis was used to identify the factors associated with the use of generic compared with brand\u2010name buprenorphine in 2008.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In OPPIDUM, 1311 individuals used buprenorphine in 2006, 1688 in 2007 and 1696 in 2008. The proportion of users of generic buprenorphine increased from 4.2% in 2006 to 31.7% in 2008. From 2006 to 2008, a decrease in intravenous use and higher than recommended dosage, with an increase in occupation, have been observed. According to the multivariate analysis, factors associated with being generic buprenorphine user compared with brand\u2010name buprenorphine user in 2008 were younger age, more education, absence of use of alcohol with buprenorphine, absence of heroin and\/or cocaine use and absence of nasal route for buprenorphine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Three years after the launch of the buprenorphine generic, the health professionals' and buprenorphine users' perception of generic can still change. Additionally, the long\u2010term impact of generic medications with abuse potential has not yet been studied. Thus, continued monitoring of buprenorphine is needed. Copyright \u00a9 2011 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.2263","type":"journal-article","created":{"date-parts":[[2011,11,23]],"date-time":"2011-11-23T09:34:54Z","timestamp":1322040894000},"page":"184-190","source":"Crossref","is-referenced-by-count":28,"title":["Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey"],"prefix":"10.1002","volume":"21","author":[{"given":"Sandra","family":"Nordmann","sequence":"first","affiliation":[{"name":"Centre d'Evaluation et d'Information de la Pharmacod\u00e9pendance\u2010Addictovigilance PACA\u2010Corse Pharmacologie Clinique, H\u00f4pital Timone, Marseille &amp; Institut des Neurosciences Cognitives de la M\u00e9diterran\u00e9e, Facult\u00e9 de m\u00e9decine, UMR 6193\u2010CNRS  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Frauger","sequence":"additional","affiliation":[{"name":"Centre d'Evaluation et d'Information de la Pharmacod\u00e9pendance\u2010Addictovigilance PACA\u2010Corse Pharmacologie Clinique, H\u00f4pital Timone, Marseille &amp; Institut des Neurosciences Cognitives de la M\u00e9diterran\u00e9e, Facult\u00e9 de m\u00e9decine, UMR 6193\u2010CNRS  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Pauly","sequence":"additional","affiliation":[{"name":"Centre d'Evaluation et d'Information de la Pharmacod\u00e9pendance\u2010Addictovigilance PACA\u2010Corse Centre Associ\u00e9, Laboratoire de Sant\u00e9 Publique, Facult\u00e9 de m\u00e9decine  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Orl\u00e9ans","sequence":"additional","affiliation":[{"name":"Centre d'Evaluation et d'Information de la Pharmacod\u00e9pendance\u2010Addictovigilance PACA\u2010Corse Centre Associ\u00e9, Laboratoire de Sant\u00e9 Publique, Facult\u00e9 de m\u00e9decine  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Pradel","sequence":"additional","affiliation":[{"name":"Centre d'Evaluation et d'Information de la Pharmacod\u00e9pendance\u2010Addictovigilance PACA\u2010Corse Centre Associ\u00e9, Laboratoire de Sant\u00e9 Publique, Facult\u00e9 de m\u00e9decine  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Mallaret","sequence":"additional","affiliation":[{"name":"Centre d'Evaluation et d'Information de la Pharmacod\u00e9pendance\u2010Addictovigilance Grenoble C.H.U. Laboratoire de Pharmacologie  Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Thirion","sequence":"additional","affiliation":[{"name":"Centre d'Evaluation et d'Information de la Pharmacod\u00e9pendance\u2010Addictovigilance PACA\u2010Corse Centre Associ\u00e9, Laboratoire de Sant\u00e9 Publique, Facult\u00e9 de m\u00e9decine  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Micallef","sequence":"additional","affiliation":[{"name":"Centre d'Evaluation et d'Information de la Pharmacod\u00e9pendance\u2010Addictovigilance PACA\u2010Corse Pharmacologie Clinique, H\u00f4pital Timone, Marseille &amp; Institut des Neurosciences Cognitives de la M\u00e9diterran\u00e9e, Facult\u00e9 de m\u00e9decine, UMR 6193\u2010CNRS  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,11,23]]},"reference":[{"issue":"2","key":"e_1_2_7_2_1","first-page":"S6","article-title":"Effect of maintenance treatments on social life. A study with general practitioners","volume":"154","author":"Bilal S","year":"2003","journal-title":"Ann Med Interne"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2003.08.005"},{"issue":"1","key":"e_1_2_7_4_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.285.1.39","article-title":"Deaths attributable to methadone vs buprenorphine in France","volume":"285","author":"Auriacombe M","year":"2001","journal-title":"JAMA"},{"issue":"4","key":"e_1_2_7_5_1","first-page":"363","article-title":"Two years follow\u2010up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow\u2010up of general practice Subutex)","volume":"48","author":"Duburcq A","year":"2000","journal-title":"Rev Epidemiol Sante Publique"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-007-0046-2"},{"key":"e_1_2_7_7_1","unstructured":"EscotsS FahetG Usages non substitutif de la bupr\u00e9norphine haut dosage en France. Graphiti \u2010 ORSMIP2004\u2010 OFDT."},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2008.07.018"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.03.025"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.03.020"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1998.93913859.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/22.6.430"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00139709-200625020-00002"},{"key":"e_1_2_7_14_1","unstructured":"Journal Officiel de la R\u00e9publique Fran\u00e7aise.Arr\u00eat\u00e9 du 7 novembre 2008 portant approbation de l'avenant n\u00b0 3 \u00e0 l'accord national relatif \u00e0 la fixation d'objectifs de d\u00e9livrance de sp\u00e9cialit\u00e9s g\u00e9n\u00e9riques. n\u00b00268 du 18 novembre2008; pp.17601.http:\/\/www.legifrance.gouv.fr\/affichTexte.do?cidTexte=JORFTEXT000019766445"},{"issue":"2","key":"e_1_2_7_15_1","first-page":"327","article-title":"Successful lung transplantation for talcosis secondary to intravenous abuse of oral drug","volume":"3","author":"Shlomi D","year":"2008","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0300-9432(73)90066-6"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2009.12.066"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0151-9638(07)91607-5"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01521.x"},{"issue":"69","key":"e_1_2_7_20_1","first-page":"1","article-title":"Use of generic High Dose Buprenorphine (HDB): about a qualitative survey","volume":"25","author":"El\u2010Haik Y","year":"2011","journal-title":"Fundam Clin Pharmacol"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.05.008"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1300\/J069v25n02_08"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1113"},{"key":"e_1_2_7_24_1","unstructured":"CanarelliT CoquelinA OFDT.Donn\u00e9es r\u00e9centes relatives aux traitements de substitution aux opiac\u00e9s.Tendancesn\u00b0 65 2009 OFDT 6 p."},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2009054"},{"key":"e_1_2_7_26_1","unstructured":"BoulosM ArdittiJ P\u00e9pinGet al.DRAMES\u2009: studies results (2002\u20132006).Le courrier des addictions 2008; (10) n\u00b01."},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.2515\/therapie:2008037"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00414-008-0291-x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730030-00007"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000050711"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2001.961014337.x"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/801984"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.9.1016"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.2307\/3172907"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2009.0009"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2006.01.011"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1681"},{"key":"e_1_2_7_38_1","first-page":"17","article-title":"The validity of self\u2010reported drug use in survey research: an overview and critique of research methods","volume":"167","author":"Harrison L","year":"1997","journal-title":"NIDA Res Monogr"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.08.011"},{"issue":"69","key":"e_1_2_7_40_1","first-page":"1","article-title":"Health status of patients under opioid maintenance therapy followed by general practitioners","volume":"25","author":"Harroche J","year":"2011","journal-title":"Fundam Clin Pharmacol"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.2263","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.2263","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.2263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T23:11:23Z","timestamp":1695510683000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.2263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,23]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1002\/pds.2263"],"URL":"https:\/\/doi.org\/10.1002\/pds.2263","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,23]]}}}